Adalta Ltd. · ASX:1AD
Adalta — Shareholder Meeting (November 2022)
35 slides from Adalta's shareholder meeting presentation, Nov 22, 2022
Slide 1: Chairman's address – 2022 AdAlta Annual General Meeting
22 November 2022 Chairman’s address – 2022 AdAlta Annual General Meeting For personal use only Ladies and gentlemen, FY22 was a busy period and one which saw AdAlta deliver a number of important value- building milestones via our AD-214 program, and in the last few weeks, we’ve reported a substantia
Slide 2: Chairman's address (continued)
We are also grateful to the Victorian Government for access to an R&D Tax Incentive Loan Advance Facility of $4 million payable on receipt of our FY23 R&D Tax rebate. We thank all those shareholders who supported AdAlta through fresh investment into For personal use only the Placement and rights iss
Slide 3: Notes to Editors – About AdAlta
Notes to Editors About AdAlta AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology For personal use only platform to solve challenging drug targeting problems and generate a promising new class of si
Slide 4: Developing high value drugs for challenging diseases
For personal use only Developing high value drugs for challenging diseases Tim Oldham PhD, CEO and Managing Director Annual General Meeting, 22 November 2022
Slide 5: Disclaimer
AGM presentation – NOVEMBER 2022 2 Disclaimer For personal use only Investment in AdAlta is subject to This presentation may contain forward- There is no guarantee that the investment risk, including possible loss looking statements regarding the Company’s research and development of income and capi
Slide 6: AdAlta at a glance
AGM presentation – NOVEMBER 2022 3 AdAlta at a glance For personal use only AdAlta’s i-body platform is enabling a high-value product pipeline in two therapeutic areas of significant unmet medical need i-body discovery platform A wholly owned fibrosis and A co-developed immuno- enables development o
Slide 7: AdAlta's purpose: developing high value drugs for challenging diseases
AGM presentation – NOVEMBER 2022 4 AdAlta’s purpose: developing high value drugs for challenging diseases For personal use only Antibodies cannot do everything! AdAlta’s i-bodies are a differentiated drug discovery platform for difficult diseases Fibrosis: degenerative, progressive, fatal AdAlta’s A
Slide 8: Achievements over past year add value to our portfolio
AGM presentation – NOVEMBER 2022 5 Achievements over past year add value to our portfolio For personal use only New indications and route of administration for AD-214 and CXCR4 program New pre-clinical data in kidney fibrosis Two clinic-ready indications Initiated pre-clinical studies (eye fibrosis)
Slide 9: AdAlta's expanded pipeline
AGM presentation – NOVEMBER 2022 6 AdAlta’s expanded pipeline For personal use only Discovery Non-clinical Clinical Indication Target Product Partner (route) Lead IND Discovery Preclinical Phase I Phase II optimisation enabling Lung fibrosis (IV) Lung fibrosis (inhaled) AD-214 Kidney fibrosis CXCR4
Slide 10: Discovery platform: i-bodies
For personal use only Discovery platform: i-bodies
Slide 11: i-bodies allow for high affinity, high specificity binding
COMPANY OVERVIEW – NOVEMBER 2022 8 i-bodies allow for high affinity, high specificity binding to targets that are intractable for traditional antibodies For personal use only Small Antibodies i-bodies Flexible, modular formats Molecules CAR cell therapy ADC/ radiotherapeutic Bi-specific Fc-fusion i-
Slide 12: AD-214 program
For personal use only AD-214 program 9
Slide 13: Four indications offer best commercial potential
AGM presentation – NOVEMBER 2022 10 Four indications offer best commercial potential, most favourable landscape For personal use only § Compelling data from preclinical tissue and animal models show that AD-214 improves outcomes Lung Kidney across a range of fibrotic diseases; partnership IPF/ILD Lu
Slide 14: Our preferred approach for AD-214 today
AGM presentation – NOVEMBER 2022 11 Our preferred approach for AD-214 today For personal use only Internal focus Progress through partnership Lung, kidney and eye fibrosis indications • Preclinical eye data, partnering discussions in next 6 months to further refine indication for next AdAlta sponsor
Slide 15: Data supports use of injectable AD-214 in lung and kidney fibrosis
AGM presentation – NOVEMBER 2022 12 Data supports use of injectable AD-214 in lung and kidney fibrosis For personal use only AD-214 reduces fibrosis score in bleomycin (BLM) mouse AD-214 is well tolerated and binds CXCR4 tightly in healthy model of kidney fibrosis1 volunteers3 6 Statistical signific
Slide 16: For personal use only
genes compared to the lasered eye with no this AD-1140.5 treatment. contraction and lesion d animal diseaselung model model, laser treatment of the mouse eye induces growth of blood hasused beenforstained the assessment to show of the retina es for the treatment of pulmonary fibrosis. vessels and su
Slide 17: Product improvements add further value to AD-214
AGM presentation – NOVEMBER 2022 14 Product improvements add further value to AD-2141 For personal use only Feasibility of inhaled AD-214 has been demonstrated – life Manufacturing and formulation initiatives support potential cycle extension strategy for IPF partners for enhanced yield and improved
Slide 18: Pharma companies continue to see value in fibrosis assets
AGM presentation – NOVEMBER 2022 15 Pharma companies continue to see value in fibrosis assets: IPF examples For personal use only Date Licensor/target Licensee/acquirer Transaction Terms Clinical Phase US$80m Upfront Aug-22 2 (Ready) US$620m Milestones Nov-21 US$254m Upfront 2 (Ready) Nov-21 €320m M
Slide 19: Co-developed immuno-oncology discovery programs
For personal use only Co-developed immuno-oncology discovery programs 16
Slide 20: About CAR-T therapies
AGM presentation – NOVEMBER 2022 17 About | CAR-T therapies For personal use only CAR-T therapies are providing new hope for patients with cancer who have failed all other options Therapy involves removing immune cells from blood and re-engineering them so they “see” cancer as a pathogen Already 6 F
Slide 21: i-CAR-T immuno-oncology assets | Carina co-development collaboration
AGM presentation – NOVEMBER 2022 18 i-CAR-T immuno-oncology assets | Carina co-development collaboration For personal use only AdAlta and Carina are combining i-bodies and a world class CAR-T platform to create i-CAR-Ts that could offer improved precision, performance and persistence ü Collaborating
Slide 22: i-CAR-T assets | Carina collaboration status
AGM presentation – NOVEMBER 2022 19 i-CAR-T assets | Carina co-development collaboration status For personal use only ü i-body enabled CAR-T (i-CAR-T) cells have been successfully generated by Carina and demonstrate in vitro cancer cell line killing (lysis)1 ü First target (target A) selected and 9
Slide 23: i-CAR-T | Valuable cell therapy partnering potential
AGM presentation – NOVEMBER 2022 20 i-CAR-T | Valuable cell therapy partnering potential at pre-clinical proof of concept For personal use only No. of Upfront payment Deal Value Upfront/target Deal value/target Date Licensee Licensor assets (US$m) (US$m) (US$m) (US$m) Jun-22 2 60 1460 30 730 Jul-20
Slide 24: About Immuno-oncology PET imaging
AGM presentation – NOVEMBER 2022 21 About | Immuno-oncology (I/O) PET imaging For personal use only Immuno-oncology (I/O) drug market is worth US$95 billion1 … … but only 20-40% of patients respond2 to therapy Granzyme B (GZMB) is produced by immune cells to kill cancer: potential biomarker of I/O d
Slide 25: GZMB i-PET imaging asset | GE Healthcare collaboration
AGM presentation – NOVEMBER 2022 22 GZMB i-PET imaging asset | GE Healthcare co-development collaboration For personal use only AdAlta and GE are co-developing a GZMB i-body PET imaging (i-PET) asset to evaluate the effectiveness of immuno-oncology drugs ü A$2.37 million revenue earned to date ü GZM
Slide 26: GZMB i-PET imaging asset | collaboration status
AGM presentation – NOVEMBER 2022 23 GZMB i-PET imaging asset | GE Healthcare co-development collaboration status For personal use only ü Panel of GZMB specific i-bodies identified ü Pre-clinical proof of concept studies and i-body optimization continuing ü Manufacturing development underway - Furthe
Slide 27: Next steps
For personal use only Next steps 24
Slide 28: Our platforms to deliver high value therapeutics
AGM presentation – NOVEMBER 2022 25 Our platforms to deliver high value therapeutics for difficult diseases For personal use only Discovery platform i-body discovery What it does Key success factors • Focuses on validated disease targets • Proprietary drug screening platforms • Discovers therapeutic
Slide 29: Our platforms work together to accelerate growth
AGM presentation – NOVEMBER 2022 26 Our platforms work together to accelerate growth For personal use only Discovery platform i-body discovery Lower cost creation of product candidate "inventory" Creates diverse, differentiated future pipeline Attracts long term co-development partners Product devel
Slide 30: Current pipeline by platform
AGM presentation – NOVEMBER 2022 27 Current pipeline by platform For personal use only Discovery platform i-body discovery Targets GPCRs Cell & gene therapy PET imaging tumour antigens biomarkers Programs CXCR4 GPCR “X” i-CAR-T GZMB Target “A” Oncology discovery collaboration with Co-discovery with
Slide 31: Our strategic priorities for near term growth
AGM presentation – NOVEMBER 2022 28 Our strategic priorities for near term growth For personal use only Discovery platform i-body discovery 1. Commence discovery on additional Carina 3. Research excellence program targets 2. Secure additional fully funded i-CAR 4. Invest in next generation i-body di
Slide 32: Upcoming milestones
AGM presentation – NOVEMBER 2022 29 Upcoming milestones | Partnering windows open, pipeline advancing For personal use only 1H CY2023 2H CY2023 AD-214 AD-214 • Manufacture extended dose toxicology material • Manufacturing for 2024 Phase II clinical studies • Additional preclinical eye, kidney fibros
Slide 33: Corporate snapshot
AGM presentation – NOVEMBER 2022 30 Corporate snapshot For personal use only Key financial details (21 Nov 2022) Share price performance (last 12 months) ASX code 1AD Market capitalisation A$16.02m Share price (12 month closing range) A$0.051 ($0.042 - 0.092) 12 month return (41)% Ordinary Shares (d
Slide 34: Investment proposition
AGM presentation – NOVEMBER 2022 31 Investment proposition For personal use only Fibrosis/inflammation Immuno-oncology AD-214 advancing to Phase II 2 x co-development collaborations to i-body platform to create value >$3b market potential in first indication1 leverage platform Multiple indication ex
Slide 35: Contact
For personal use only Contact: Tim Oldham, CEO and Managing Director enquiries@adalta.com.au www.adalta.com.au